-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades RAPT Therapeutics to Neutral, Announces $58 Price Target

Benzinga·01/20/2026 17:34:54
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral and announces $58 price target.